CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) Director Richard Young purchased 16,378 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $1.65 per share, with a total value of $27,023.70. Following the completion of the transaction, the director owned 186,388 shares in the company, valued at $307,540.20. This trade represents a 9.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
CAMP4 Therapeutics Trading Down 3.6%
NASDAQ:CAMP traded down $0.15 during trading hours on Wednesday, hitting $4.01. The stock had a trading volume of 86,050 shares, compared to its average volume of 176,472. The company has a market cap of $208.24 million, a PE ratio of -1.70 and a beta of 0.22. The business has a 50 day simple moving average of $4.02 and a two-hundred day simple moving average of $4.31. CAMP4 Therapeutics Corporation has a 1-year low of $1.32 and a 1-year high of $7.75.
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last announced its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The business had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. Research analysts expect that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current fiscal year.
Hedge Funds Weigh In On CAMP4 Therapeutics
Analyst Ratings Changes
CAMP has been the topic of a number of recent analyst reports. Zacks Research lowered shares of CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Rodman & Renshaw began coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.36.
View Our Latest Report on CAMP4 Therapeutics
CAMP4 Therapeutics Company Profile
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Featured Articles
- Five stocks we like better than CAMP4 Therapeutics
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
